Patient-Derived Tumor Organoids: New Progress and Opportunities to Facilitate Precision Cancer Immunotherapy

Ji Wang; Chao Chen; Chao Chen; Chao Chen; Lu Wang; Mingjun Xie; Mingjun Xie; Xinyang Ge; Sufan Wu; Yong He; Yong He; Yong He; Yong He; Xiaozhou Mou; Chenyang Ye; Chenyang Ye; Chenyang Ye; Yi Sun

doi:10.3389/fonc.2022.872531

Frontiers in Oncology (Apr 2022)

Patient-Derived Tumor Organoids: New Progress and Opportunities to Facilitate Precision Cancer Immunotherapy

Ji Wang,
Chao Chen,
Chao Chen,
Chao Chen,
Lu Wang,
Mingjun Xie,
Mingjun Xie,
Xinyang Ge,
Sufan Wu,
Yong He,
Yong He,
Yong He,
Yong He,
Xiaozhou Mou,
Chenyang Ye,
Chenyang Ye,
Chenyang Ye,
Yi Sun

Affiliations

Ji Wang: Center for Plastic & Reconstructive Surgery, Department of Plastic & Reconstructive Surgery, Zhejiang Provincial People’s Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, China
Chao Chen: Department of Colorectal Surgery and Oncology, Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
Chao Chen: Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
Chao Chen: Cancer Center, Zhejiang University, Hangzhou, China
Lu Wang: Center for Plastic & Reconstructive Surgery, Department of Plastic & Reconstructive Surgery, Zhejiang Provincial People’s Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, China
Mingjun Xie: State Key Laboratory of Fluid Power and Mechatronic Systems, School of Mechanical Engineering, Zhejiang University, Hangzhou, China
Mingjun Xie: Key Laboratory of Materials Processing and Mold, Zhengzhou University, Zhengzhou, China
Xinyang Ge: College of Letters and Science, University of California, Los Angeles, Los Angeles, CA, United States
Sufan Wu: Center for Plastic & Reconstructive Surgery, Department of Plastic & Reconstructive Surgery, Zhejiang Provincial People’s Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, China
Yong He: Cancer Center, Zhejiang University, Hangzhou, China
Yong He: State Key Laboratory of Fluid Power and Mechatronic Systems, School of Mechanical Engineering, Zhejiang University, Hangzhou, China
Yong He: Key Laboratory of Materials Processing and Mold, Zhengzhou University, Zhengzhou, China
Yong He: Key Laboratory of 3D Printing Process and Equipment of Zhejiang Province, College of Mechanical Engineering, Zhejiang University, Hangzhou, China
Xiaozhou Mou: Center for Plastic & Reconstructive Surgery, Department of Plastic & Reconstructive Surgery, Zhejiang Provincial People’s Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, China
Chenyang Ye: Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
Chenyang Ye: Cancer Center, Zhejiang University, Hangzhou, China
Chenyang Ye: Department of Medical Oncology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China
Yi Sun: Center for Plastic & Reconstructive Surgery, Department of Plastic & Reconstructive Surgery, Zhejiang Provincial People’s Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, China

DOI: https://doi.org/10.3389/fonc.2022.872531
Journal volume & issue: Vol. 12

Abstract

Read online

Cancer immunotherapy has revolutionized the field of cancer treatment in recent years. However, not all patients receiving cancer immunotherapy exhibit durable responses, and reliable, high-throughput testing platforms are urgently needed to guide personalized cancer immunotherapy. The ability of patient-derived tumor organoids to recapitulate pivotal features of original cancer tissues makes them useful as a preclinical model for cancer research and precision medicine. Nevertheless, many challenges exist in the translation of tumor organoid research to clinical decision making. Herein we discuss the applications of patient-derived tumor organoid models and the advances and potential of using complex immune-organoid systems as testing platforms to facilitate precision cancer immunotherapy. In addition, we highlight intriguing applications of tumor organoids with novel multi-omics in preclinical cancer research, highlighting genetic editing, proteomics, and liquid biopsy.

Published in Frontiers in Oncology

ISSN: 2234-943X (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.frontiersin.org/journals/oncology/

About the journal

Abstract

Keywords